Standards of care for type 2 diabetes in China

Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China Department of Endocrinology, Peking University People’s Hospital, Beijing, China Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China Department of Endocrinology, Chinese People’s Liberation Army General Hospital, Beijing, China Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital and the Diabetes Center, Central South University, Changsha, China Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China Department of Endocrinology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China Department of Endocrinology, Qilu Hospital of Shandong University, Ji’nan, China Department of Endocrinology, Beijing Hospital, Beijing, China Department of Endocrinology, Peking University First Hospital, Beijing, China Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi’an, China Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China Department of Endocrinology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China Department of Endocrinology, The First Hospital of China Medical University, Shenyang, China Department of Endocrinology, Affiliated Hospital of Guiyang Medical University, Guiyang, China Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China Department of Endocrinology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China Department of Endocrinology, Heilongjiang Provincial Hospital, Harbin, China Department of Endocrinology, China Japan Friendship Hospital, Beijing, China

[1]  V. Basevi.  Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[2]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[3]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[4]  Dang Qing,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance The , 2022 .

[5]  V. Mohan,et al.  Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. , 2009, Diabetes research and clinical practice.

[6]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[7]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[8]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[9]  D. Nathan.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[10]  Weiqing Wang,et al.  Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy , 2011, Expert opinion on pharmacotherapy.

[11]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[12]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[13]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[14]  Bo Zhang,et al.  The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study , 2008, The Lancet.

[15]  G. Duvel.  The study group. , 1980 .

[16]  L. Kong,et al.  [A description on the Chinese national nutrition and health survey in 2002]. , 2005, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[17]  M. Woodward,et al.  Blood glucose and risk of cardiovascular disease in the Asia Pacific region. , 2004, Diabetes care.

[18]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[19]  Song-min Huang,et al.  Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[20]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes , 2012 .

[21]  V. Mohan,et al.  Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. , 2009, Diabetes research and clinical practice.

[22]  J. Foley,et al.  Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[23]  J. Dungan.  Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study , 2011 .

[24]  Li Yan.  The effects of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients , 2003 .

[25]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[26]  J. Ge,et al.  Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. , 2010, Diabetes research and clinical practice.

[27]  Idf Clinical Guidelines Task Force.  Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[28]  Diabetes Control.  Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. , 2000, Diabetes care.

[29]  J. Shaw,et al.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[30]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[31]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .

[32]  Jai Radhakrishnan,et al.  Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[33]  [A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author's transl)]. , 1981, Zhonghua nei ke za zhi.

[34]  Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial , 2013, PloS one.

[35]  W. Jia,et al.  [Evaluation of the four simple methods in the diagnosis of diabetic peripheral neuropathy]. , 2006, Zhonghua yi xue za zhi.

[36]  Linuo Zhou,et al.  High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shanghai. , 2008, Journal of diabetes and its complications.

[37]  R. Collins,et al.  Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[38]  W. Jia,et al.  Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities , 2007, Diabetologia.

[39]  Y. Yang,et al.  An Evaluation of the Diabetic Kidney Disease Definition in Chinese Patients Diagnosed with Type 2 Diabetes Mellitus , 2009, The Journal of international medical research.

[40]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[41]  W. Ambrosius,et al.  Update of the ACCORD Eye Study. , 2011, The New England journal of medicine.

[42]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[43]  J. Hsia,et al.  Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes , 2006, Diabetes Care.

[44]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[45]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[46]  Yingying Luo,et al.  Comparisons of the Efficacy of Alpha Glucosidase Inhibitors on Type 2 Diabetes Patients between Asian and Caucasian , 2013, PloS one.

[47]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[48]  Qifu Li,et al.  Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial , 2013, PloS one.

[49]  Wenying Yang,et al.  Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. , 2014, The lancet. Diabetes & endocrinology.

[50]  S. Schinner,et al.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[51]  Dan Ziegler,et al.  Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.

[52]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[53]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[54]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[55]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[56]  H. Tian,et al.  Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China. , 2007, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[57]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, Journal of the American Medical Association (JAMA).

[58]  P. Wilson,et al.  Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes , 2010, Diabetes Care.

[59]  M. S. Kirkman,et al.  Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011 .

[60]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[61]  J. O'Callaghan,et al.  An Update on the Pharmacological Management of Post-Herpetic Neuralgia and Painful Diabetic Neuropathy , 2008, CNS drugs.

[62]  S. Grundy,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2006, Diabetes Care.

[63]  H. Gerstein,et al.  The Effect of Oral Antidiabetic Agents on A1C Levels , 2010, Diabetes Care.

[64]  K. Dou,et al.  Prevalence of diabetes among men and women in China. , 2010, The New England journal of medicine.

[65]  W. Bretz,et al.  Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.

[66]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[67]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[68]  K. Fox,et al.  Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. , 2013, The American journal of medicine.

[69]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[70]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[71]  Chong-Zhi Wang,et al.  Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. , 2014, The Journal of clinical endocrinology and metabolism.

[72]  B. Howard,et al.  Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.

[73]  H. Tian,et al.  Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial , 2008, The Lancet.

[74]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[75]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[76]  H. Kramer,et al.  Screening for kidney disease in adults with diabetes. , 2005, Diabetes care.

[77]  R. Sigal,et al.  Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta‐analysis of controlled clinical trials , 2002, JAMA.

[78]  Clyne,et al.  Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. , 1993, Journal of hypertension.

[79]  D. Moher,et al.  WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. , 2015, The Cochrane database of systematic reviews.

[80]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[81]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[82]  X. Pan,et al.  Prevalence of Diabetes and Its Risk Factors in China, 1994 , 1997, Diabetes Care.

[83]  T. Md.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin , 2004, Diabetologia.

[84]  J. Weng,et al.  Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. , 2004, Diabetes care.

[85]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[86]  Linuo Zhou,et al.  Performance and comparison of the Cockcroft–Gault and simplified Modification of Diet in Renal Disease formulae in estimating glomerular filtration rate in a Chinese Type 2 diabetic population , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[87]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[88]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[89]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[90]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[91]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[92]  Will G. Hopkins,et al.  Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: a Meta-Analysis , 2007, Diabetes Care.

[93]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[94]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[95]  L. Groop.  Sulfonylureas in NIDDM , 1992, Diabetes Care.

[96]  A. Veves,et al.  Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. , 2008, Pain medicine.

[97]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[98]  J. Allenberg,et al.  High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[99]  Kevin Weiss,et al.  The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus , 2003, Annals of Internal Medicine.